Study of MDG1015 for certain cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called MDG1015 for people with specific types of ovarian, stomach, or soft tissue cancers. It aims to see if it is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and weigh at least 40 kg (88 lbs) or 50 kg (110 lbs) depending on the dose level.
- You must have one of these cancers: high-grade serous or endometrioid ovarian cancer, primary peritoneal or fallopian tube cancer, stomach or esophageal cancer, or certain sarcomas (myxoid liposarcoma or synovial sarcoma).
- Your tumor must have a specific genetic marker (HLA-A*02:01) and produce certain proteins (NY-ESO-1 and/or LAGE-1a).
- You must have tried all standard treatments that are known to help your type of cancer.
- You must have tumors that can be measured and be expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
This trial tests a new drug, MB0151, for adults with advanced solid tumors that have somatostatin receptors and have not responded to standard treatments. It aims to see if MB0151 is safe and can shrink tumors.
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.